{"id":781333,"date":"2023-08-31T08:59:46","date_gmt":"2023-08-31T12:59:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/"},"modified":"2023-08-31T08:59:46","modified_gmt":"2023-08-31T12:59:46","slug":"vera-therapeutics-scheduled-to-present-at-september-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/","title":{"rendered":"Vera Therapeutics Scheduled to Present at September Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BRISBANE, Calif., Aug.  31, 2023  (GLOBE NEWSWIRE) &#8212; Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company\u2019s management team will present and participate in one-on-one meetings at four investor conferences being held next month.<\/p>\n<p>\n        <strong><br \/>\n          <u>Investor Conference Details: <\/u><br \/>\n        <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Citi 18<\/strong><br \/>\n          <sup><br \/>\n            <strong>th<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual BioPharma Conference<br \/><\/strong>Format: Management hosting investor meetings<br \/>Date: Wednesday, September 6, 2023<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>H.C. Wainwright 25<\/strong><br \/>\n          <sup><br \/>\n            <strong>th<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Global Investment Conference<br \/><\/strong>Format: Corporate Presentation and host investor meetings<br \/>Date and Time: Monday, September 11, 2023, 7:00 AM ET<br \/>Webcast: <a href=\"https:\/\/journey.ct.events\/view\/9a2283f1-f1e7-419d-8bd4-401151e5a75c\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/journey.ct.events\/view<\/a><a href=\"https:\/\/journey.ct.events\/view\/9a2283f1-f1e7-419d-8bd4-401151e5a75c\" rel=\"nofollow noopener\" target=\"_blank\"><\/p>\n<p><\/a>The H.C. Wainwright presentation will be available for 90 days and can be accessed by visiting the \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2_ShfZBqvifOPP9JnFn-JM23L2tH9KBAUFWi2pN3fF9tnRY9qM2lx7yjr7ouNNE-bzZnfPy2Q3hH7pn1JuvJRfhTdrOjZK4MzTQ3oDRiw2eOVEatDRQuxlKAuYuFfWG4\" rel=\"nofollow noopener\" target=\"_blank\">Investor Calendar<\/a>\u201d section of the Vera Therapeutics website.<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Stifel 2023 Immunology and Inflammation Virtual Summit <\/strong><br \/>\n          <br \/>Format: Fireside Chat<br \/>Date and Time: Wednesday, September 20, 2023, 2:15-3:00 PM ET<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>2023 Cantor Global Healthcare Conference <\/strong><br \/>\n          <br \/>Format: Fireside Chat and host investor meetings<br \/>Date and Time: Wednesday, September 27, 2023, 11:25-11:55 AM ET<\/li>\n<\/ul>\n<p>Investors interested in scheduling a meeting with management during one of the investor conferences listed above should contact their Citi, H.C. Wainwright, Stifel, or Cantor sales representative.<\/p>\n<p>\n        <strong>About Vera Therapeutics<\/strong><br \/>\n        <br \/>Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera\u2019s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera\u2019s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger\u2019s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r6Sy24Kp0FqTsQqxL1oIR0aXGYwYiXnYEOBsjfq5Bi0ILr6qDwi_pT7sGZWni_AvKfmIAhu2RwB-RX26YCg0jQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.veratx.com<\/a>.<\/p>\n<p>\n        <u>For more information, please contact:<\/u>\n      <\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Joyce Allaire<br \/>LifeSci Advisors<br \/>212-915-2569<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_owX09CPT3OnU55dF4r8OxdN4CgO2scfqNVDnydWQLL5lUdvKz1AUyGIvc9lg22JB6hcCfMfZ-DwM-327vfswQSMluA9zaW66r2eSQJzhc4ZOpZ96zkgmq0M6VQ4M_I5\" rel=\"nofollow noopener\" target=\"_blank\">jallaire@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Minyan Weiss<br \/>Uncapped Communications, Inc. <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vhanD075Lomgdy5Y3QV58aU_FGMpX03AhbnrQifcttBuHT0aUWZHlQoYzZfcVmke1URZ85TMLtQPngng-gINquupxFnRJgF_j4wsgPMclfX4a00vs9UahavJ6Hd7Nwznk9CZurUccRYKUuDeuDsMbkQncZFuHWR6ITPQJkHWhnxYASUXnQvmQ2rTRvbXbpW27Z5FrWChIxDR0GMIkpRNHywA0nGZTxqkTqaWbttpF7bVaOZ5r2913i4JnD2kp5eSWqhAOb6g0XQ_lRL0LuHAMsEq7So0fQwNjJxc9K8Id8tbyDbtXL9flGCc7-sGVB2yJvvdtjIM2S0Cwad9PrrpCsyCAnqKswNZVuNaxST1vIc=\" rel=\"nofollow noopener\" target=\"_blank\">Minyan.Weiss@uncappedcommunications.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzkxNCM1NzkxMjY1IzIyMDc0Njk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NmQzNTFjZGUtN2RiMC00OTliLTk0ZDQtN2IwYjUzOTIxZWMxLTEyMTkwMjI=\/tiny\/Vera-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BRISBANE, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) &#8212; Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company\u2019s management team will present and participate in one-on-one meetings at four investor conferences being held next month. Investor Conference Details: Citi 18 th Annual BioPharma ConferenceFormat: Management hosting investor meetingsDate: Wednesday, September 6, 2023 H.C. Wainwright 25 th Annual Global Investment ConferenceFormat: Corporate Presentation and host investor meetingsDate and Time: Monday, September 11, 2023, 7:00 AM ETWebcast: https:\/\/journey.ct.events\/view The H.C. Wainwright presentation will be available for 90 days and can be accessed by visiting the \u201cInvestor Calendar\u201d section of the Vera Therapeutics website. Stifel &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vera Therapeutics Scheduled to Present at September Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-781333","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vera Therapeutics Scheduled to Present at September Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vera Therapeutics Scheduled to Present at September Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BRISBANE, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) &#8212; Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company\u2019s management team will present and participate in one-on-one meetings at four investor conferences being held next month. Investor Conference Details: Citi 18 th Annual BioPharma ConferenceFormat: Management hosting investor meetingsDate: Wednesday, September 6, 2023 H.C. Wainwright 25 th Annual Global Investment ConferenceFormat: Corporate Presentation and host investor meetingsDate and Time: Monday, September 11, 2023, 7:00 AM ETWebcast: https:\/\/journey.ct.events\/view The H.C. Wainwright presentation will be available for 90 days and can be accessed by visiting the \u201cInvestor Calendar\u201d section of the Vera Therapeutics website. Stifel &hellip; Continue reading &quot;Vera Therapeutics Scheduled to Present at September Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-31T12:59:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzkxNCM1NzkxMjY1IzIyMDc0Njk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vera Therapeutics Scheduled to Present at September Investor Conferences\",\"datePublished\":\"2023-08-31T12:59:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\\\/\"},\"wordCount\":380,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzkxNCM1NzkxMjY1IzIyMDc0Njk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\\\/\",\"name\":\"Vera Therapeutics Scheduled to Present at September Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzkxNCM1NzkxMjY1IzIyMDc0Njk=\",\"datePublished\":\"2023-08-31T12:59:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzkxNCM1NzkxMjY1IzIyMDc0Njk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzkxNCM1NzkxMjY1IzIyMDc0Njk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vera Therapeutics Scheduled to Present at September Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vera Therapeutics Scheduled to Present at September Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Vera Therapeutics Scheduled to Present at September Investor Conferences - Market Newsdesk","og_description":"BRISBANE, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) &#8212; Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company\u2019s management team will present and participate in one-on-one meetings at four investor conferences being held next month. Investor Conference Details: Citi 18 th Annual BioPharma ConferenceFormat: Management hosting investor meetingsDate: Wednesday, September 6, 2023 H.C. Wainwright 25 th Annual Global Investment ConferenceFormat: Corporate Presentation and host investor meetingsDate and Time: Monday, September 11, 2023, 7:00 AM ETWebcast: https:\/\/journey.ct.events\/view The H.C. Wainwright presentation will be available for 90 days and can be accessed by visiting the \u201cInvestor Calendar\u201d section of the Vera Therapeutics website. Stifel &hellip; Continue reading \"Vera Therapeutics Scheduled to Present at September Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-31T12:59:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzkxNCM1NzkxMjY1IzIyMDc0Njk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vera Therapeutics Scheduled to Present at September Investor Conferences","datePublished":"2023-08-31T12:59:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/"},"wordCount":380,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzkxNCM1NzkxMjY1IzIyMDc0Njk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/","name":"Vera Therapeutics Scheduled to Present at September Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzkxNCM1NzkxMjY1IzIyMDc0Njk=","datePublished":"2023-08-31T12:59:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzkxNCM1NzkxMjY1IzIyMDc0Njk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzkxNCM1NzkxMjY1IzIyMDc0Njk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-scheduled-to-present-at-september-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vera Therapeutics Scheduled to Present at September Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=781333"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781333\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=781333"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=781333"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=781333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}